Clinical trials: Blood-Borne Infections
Neurocysticercosis, HIV/AIDS
The Burden of (Neuro)Cysticercosis Among People Living With HIV in Rural Tanzania
This study aims to compare the burden of neurocysticercosis among people living with HIV to people not infected with HIV.
- Trial name
- CYSTINET_Tz (NCT03851419)
- Testing
- Diagnosis of (Neuro)cysticercosis
- Where
- Tanzania
- Volunteers
- 2,584 people, healthy volunteers welcome
- Sponsor
- Technical University of Munich
HIV Infections
Salvage Treatment, Resistance Testing, and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV Treatment
The purpose of this study is to test another way to control the amount of HIV in the blood (viral load). Studies show that stopping all anti-HIV drugs for a time before switching to new anti-HIV drugs may improve the response in…
- Trial name
- NCT00011128
- Testing
- Antiretroviral Treatment Interruption
- Where
- 30 sites in United States, Puerto Rico
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults
Primary purpose of this study is to compare the efficacy and safety of two different nevirapine (Viramune) dosing regimens (once daily (QD) and twice daily (BID) application) and of atazanavir/ritonavir (Reyataz/Norvir), all on…
- Trial name
- NCT00389207
- Testing
- nevirapine bid, nevirapine qd, atazanavir
- Where
- 68 sites in Argentina, Germany and 8 more
- Volunteers
- 576 people
- Sponsor
- Boehringer Ingelheim
HIV Infections, Heroin Dependence
Directly Administered Antiretroviral Therapy (DAART) Among HIV-1infected Injecting Drug Users (IDUs) in Chennai, India
Though the HIV epidemic in India is predominantly among heterosexual populations, it is estimated that there are approximately 1.1 million injection drug users (IDUs) in India with HIV prevalence as high as 64% among IDUs in…
- Trial name
- DAART+ (NCT00709007)
- Testing
- Directly Administered Antiretroviral Therapy (DAART), SAT
- Where
- India
- Sponsor
- Johns Hopkins University
HIV Infection
Use of Incentives to Engage Drug Users in HIV Therapy
Highly active antiretroviral therapy (HAART), the current standard of care for treatment of HIV infection, is highly effective when taken appropriately.
- Trial name
- Incentives-1 (NCT01526421)
- Testing
- monetary reinforcer
- Where
- Canada
- Volunteers
- 301 people
- Sponsor
- University of British Columbia
Human Immunodeficiency Virus, STI
A Savings Intervention to Reduce Men's Engagement in HIV Risk Behaviors
This randomized control trial will test an economic intervention to reduce Kenyan men's engagement in behaviors that increase the risk of HIV/STIs.
- Conditions
- Human Immunodeficiency Virus, STI, Alcohol Consumption, Incentives
- Trial name
- NCT05385484
- Testing
- Receives mobile banking account with incentives to save, Basic Health and financial education
- Where
- Kenya
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
HIV Infections
Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients
This observational study is supposed to assess (under conditions of clinical practice in daily routine) whether treatment with Viramune (nevirapine) in combination with ARV, e.g.
- Trial name
- NCT00876733
- Where
- 66 sites in Germany
- Volunteers
- 605 people
- Sponsor
- Boehringer Ingelheim
Infection, Human Immunodeficiency Virus, HIV Infections
Incidence of Human Immunodeficiency Virus-1 (HIV-1) Infection in HIV-1 Uninfected High Risk Men Who Have Sex With Men
Studies to assess the effectiveness of interventions to prevent HIV infection depend upon robust estimates of Baseline HIV incidence rates.
- Trial name
- NCT03310515
- Testing
- Risk reduction counseling, Social harm interview, Computer-Assisted Self Interviewing technique
- Where
- 9 sites in China
- Volunteers
- 578 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
Atazanavir (BMS-232632) in Combination With Ritonavir or Saquinavir, and Lopinavir/Ritonavir, Each With Tenofovir and a Nucleoside in Subjects With HIV
The purpose of this study is to learn how well atazanavir (ATV) works in combination with ritonavir (RTV) or saquinavir (SQV) with tenofovir (TDF) and a nucleoside to reduce the viral load of treatment experienced subjects with…
- Trial name
- NCT00035932
- Testing
- Atazanavir + ritonavir + tenofovir + nucleoside, Atazanavir + saquinavir + tenofovir + nucleoside, Lopinavir/ritonavir + tenofovir + nucleoside
- Where
- 29 sites in United States
- Volunteers
- 571 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus
TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435
The purpose of the study is to investigate the effect of moderate and severe hepatic impairment on the pharmacokinetics of TMC435.
- Trial name
- NCT01046058
- Testing
- TMC435
- Where
- 3 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
HIV Infection
The Self-Collection Study: a Study of Self-collected HPV Testing and Results Counseling
Cervical cancer is the second most common type of cancer among women worldwide. Women with human immunodeficiency virus (HIV) bear a disproportionate burden of cervical cancer and its precursor, cervical intraepithelial neoplasia…
- Trial name
- NCT01843478
- Testing
- Self-Collected HPV Test, Usual Care
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Johns Hopkins University
HIV Infections
Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of polyvalent env (A,B,C,A/E)/gag (C) DNA and gp120 (A,B,C,A/E) protein vaccines (PDPHV201401) co-administered together with or without adjuvant…
- Trial name
- NCT04927585
- Testing
- env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Worcester HIV Vaccine
HIV Infections, Sexually Transmitted Diseases
Defining the PrEP Care Continuum Among Recently Incarcerated Men at High-Risk for HIV Infection
Background: Several major studies have demonstrated the success of Truvada as pre-exposure prophylaxis (PrEP) in preventing HIV infection.The CDC guidelines recommend PrEP for people who are at elevated risk of HIV including men…
- Trial name
- NCT04240509
- Testing
- Emtricitabine / Tenofovir
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- The Miriam Hospital
Condomless Sex, Human Immunodeficiency Virus (HIV)
Cape Town Young Women's Health CoOp
This two-arm cluster randomized trial tested a gender-focused comprehensive HIV testing and counselling (HTC) program, the Young Women's Health CoOp (YWHC) with a standard HTC program and targeted female adolescents (aged 16-19)…
- Conditions
- Condomless Sex, Human Immunodeficiency Virus (HIV), Sexually Transmitted Infections (STIs), Alcohol and Drug Use
- Trial name
- NCT02974998
- Testing
- Young Women's Health CoOp (YWHC), Standard HTC
- Where
- South Africa
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- RTI International
Chronic Hepatitis B Virus Infection, Hepatitis B
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
The study is intended to evaluate the efficacy and safety of 2 different doses of DAP/TOM followed by bepirovirsen in participants living with CHB on standard of care nucleos(t)ide analogue (NA) therapy.
- Trial name
- B-UNITED (NCT06537414)
- Testing
- Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen
- Where
- 80 sites in United States, Australia and 17 more
- Volunteers
- 283 people
- Sponsor
- GlaxoSmithKline
HBV, HCV
Non-interventional Study to Assess the Number of People With Untreated/Unknown HBV + HDV and HCV in South-East Austria
The HEAL-S study is a non-interventional study with retrospective data analysis. It consists of two parts. First a retrospective analysis based on nucleic acid testing (NAT) results will be performed.
- Conditions
- HBV, HCV, HDV, Coinfection
- Trial name
- HEAL-S (NCT06834178)
- Where
- Austria
- Volunteers
- 100 people
- Sponsor
- Vanessa Stadlbauer-Koellner, MD
Chronic Hepatitis C - Genotype 3
Chronic Hepatitis C (CHC) - Genotype 3 Infection in Canada
Hepatitis C is a small RNA virus spread by blood to blood contamination. There are to date 6 known genotypes and within each there are several subtypes.
- Trial name
- NCT01100749
- Where
- 2 sites in Canada
- Volunteers
- 25 people
- Sponsor
- University Health Network, Toronto
Hepatitis C, Chronic
A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis C
This 3-arm study assessed the safety and efficacy of combination treatment with peginterferon alfa-2a + ribavirin in participants with chronic hepatitis C.
- Trial name
- NCT00800748
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 35 sites in Czechia, Slovakia
- Volunteers
- 372 people
- Sponsor
- Hoffmann-La Roche
AIDS
Acquired Immunodeficiency Syndrome(AIDS) and Tuberculosis(Tb) Co-infection Treatment Strategies Study of China.
To determine the best time to begin anti-HIV(Acquired Immunodeficiency Syndrome) treatment in individuals who co-infected with HIV and tuberculosis (Tb).
- Trial name
- NCT01344148
- Testing
- INH RIF Rifb PZA EMB AZT 3TC D4T EFV
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Shanghai Public Health Clinical Center
HIV Infections
An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy
The purpose of this study is to see if it is effective to give HIV positive patients recombinant interleukin-2 (rIL-2) in addition to anti-HIV therapy.
- Trial name
- ESPRIT (NCT00004978)
- Testing
- Recombinant interleukin-2 (rIL-2)
- Where
- 248 sites in United States, Argentina and 23 more
- Volunteers
- 4,150 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.